ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
A new hope in the management of hematologic malignancy: immunotherapy
Abstract
In recent years, Hodgkin's and Non-Hodgkin's lymphoma incidence is increasing all over the world. In the United States, lymphomas are the fourth most common malignancies among all. Lymphoid malignancies have a broad spectrum from mild indolent types, such as chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL), follicular lymphoma(FL), marginal zone lymphoma, and cutaneous T-cell lymphoma to aggressive types such as diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma, Burkitt's lymphoma, peripheral T-cell lymphoma. With better response rates to chemotherapy, longer disease-free survival and overall survival rates, lymphomas have satisfactory treatment results rather than solid organ tumors for oncologists. Throughout history, conventional chemotherapy agents, radiotherapy and their combinations have been used for the treatment of lymphoma. Especially, in the early stages of Hodgkin's lymphoma, a rate of 85-90% complete remission and high rate long-term remission can be achieved. However, despite this high response rate, 15-30% of patients are resistant to treatment. With current therapiesresponse rate and persistent long-term remission rate in Non-Hodgkin's lymphomas are around 50%. Therefore, new therapeutic approaches such as immunotherapy and the using of cytotoxic properties of T cells against tumor has been developed and used in recent years for the treatment of refractory lymphoma.

Keywords : Hematologic malignancy, immunotherapy, new target

Download Article


1. Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapiesin lymphoid malignancies. Nat Rev Clin Oncol. 2016;13(1):25-40.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014 [publishedcorrection appears in CA Cancer J Clin. 2014;64(5):364]. CA Cancer JClin. 2014;64(1):9-29. doi:10.3322/caac.21208
3. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication ofB-lineage cells and regression of lymphoma in a patient treated withautologous T cells genetically engineered to recognize CD19. Blood.2010;116(20):4099-4102. doi:10.1182/blood-2010-04-281931
4. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion andremissions of malignancy along with cytokine-associated toxicity ina clinical trial of anti-CD19 chimeric-antigen-receptor-transduced Tcells. Blood. 2012;119(12):2709-2720. doi:10.1182/blood-2011-10-384388
5. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1receptors inhibit T-cell activation by distinct mechanisms. Mol CellBiol. 2005;25(21):9543-9553. doi:10.1128/MCB.25.21.9543-9553.2005
6. Pardoll DM. The blockade of immune checkpoints in cancerimmunotherapy. Nat Rev Cancer. 2012;12(4):252-264.doi:10.1038/nrc3239
7. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1promotes T-cell apoptosis: a potential mechanism of immune evasion[published correction appears in Nat Med 2002;8(9):1039]. Nat Med.2002;8(8):793-800. doi:10.1038/nm730
8. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloiddendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562-567. doi:10.1038/nm863
9. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinibin relapsed or refractory mantle-cell lymphoma. N Engl J Med.2013;369(6):507-516. doi:10.1056/NEJMoa1306220
10. Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat RevDrug Discov. 2012;11(1):19-20. doi:10.1038/nrd3629
11. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase IIstudy of brentuximab vedotin for patients with relapsed or refractoryHodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189. doi:10.1200/JCO.2011.38.0410
12. Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractoryCD30+ lymphomas: a bridge to allogeneic transplantation inapproximately one quarter of patients treated on a Named PatientProgramme at a single UK center. Haematologica. 2013;98(4):611-614.doi:10.3324/haematol.2012.069393
13. Sasse S, Rothe A, Goergen H, et al. Brentuximab vedotin (SGN-35) inpatients with transplant-naive relapsed/refractory Hodgkin lymphoma.Leuk Lymphoma. 2013;54(10):2144-2148. doi:10.3109/10428194.2013.775434
14. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab:a historical perspective. Pharmacol Ther. 2012;136(3):334-342.doi:10.1016/j.pharmthera.2012.07.013
15. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumabin previously treated chronic lymphoid leukemia. N Engl J Med.2014;371(3):213-223. doi:10.1056/NEJMoa1400376
16. Castelli R, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, CugnoM. Current and emerging treatment options for patients with relapsedmyeloma. Clin Med Insights Oncol. 2013;7:209-219. doi:10.4137/CMO.S8014
17. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitorof phosphatidylinositol 3-kinase-δ, as therapy for previously treatedindolent non-Hodgkin lymphoma. Blood. 2014;123(22):3406-3413.doi:10.1182/blood-2013-11-538546
18. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab inrelapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997-1007. doi: 10.1056/NEJMoa1315226
19. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle celllymphoma in the United States between 1992 and 2004. Cancer.2008;113(4):791-798. doi:10.1002/cncr.23608
20. Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide inpatients with mantle-cell lymphoma who relapsed or progressed afteror were refractory to bortezomib: phase II MCL-001 (EMERGE) study.J Clin Oncol. 2013;31(29):3688-3695. doi:10.1200/JCO.2013.49.2835
21. Castelli R, Gualtierotti R, Orofino N, Losurdo A, Gandolfi S, CugnoM. Current and emerging treatment options for patients with relapsedmyeloma. Clin Med Insights Oncol. 2013;7:209-219. doi:10.4137/CMO.S8014
22. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy:understanding the characteristics of tumor-infiltrating immune cellsand their therapeutic implications. Cell Mol Immunol. 2020;17(8):807-821. doi:10.1038/s41423-020-0488-6
Article available in :
Volume 1, Issue 1, 2023
Page : 20-23
https://doi.org/10.51271/ICJIM-0004
Article Information
Received : 02 Şub 2023
Accepted : 20 Şub 2023
Published : 25 Şub 2023
Corresponding Author :

Bilgin Bahadır Başgöz: Department of Internal Medicine, Gülhane School of Medicine, Health Sciences University, Ankara, Turkiye

[email protected]
Citation : Başgöz BB, Solmaz İ, Kılıç J. A new hope in the management of hematologic malignancy: immunotherapy. Intercont J Int Med 2023; 1(1): 20-23

Read: 246
Cited: 0
Download : 276
_Footer